These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 17179034)

  • 21. Erectile dysfunction as a risk factor for coronary heart disease: implications for prevention.
    Tikkanen MJ; Jackson G; Tammela T; Assmann G; Palomäki A; Kupari M; Olsson A
    Int J Clin Pract; 2007 Feb; 61(2):265-8. PubMed ID: 17263713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thermal therapy for the management of cardiovascular pathology].
    Persiianova-Dubrova AL; Badalov NG
    Vopr Kurortol Fizioter Lech Fiz Kult; 2013; (3):57-61. PubMed ID: 23819419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ageing endothelium, cardiovascular risk and disease in man.
    Versari D; Daghini E; Virdis A; Ghiadoni L; Taddei S
    Exp Physiol; 2009 Mar; 94(3):317-21. PubMed ID: 18805864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS; Morrow DA; Jablonski KA; Rice MM; Warnica JW; Domanski MJ; Hsia J; Gersh BJ; Rifai N; Ridker PM; Pfeffer MA; Braunwald E;
    Circulation; 2007 Mar; 115(12):1528-36. PubMed ID: 17372173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coronary endothelial dysfunction and cerebrovascular events.
    Hellstrom HR
    Circulation; 2004 May; 109(18):e208. PubMed ID: 15136512
    [No Abstract]   [Full Text] [Related]  

  • 26. Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study.
    Walter MF; Jacob RF; Bjork RE; Jeffers B; Buch J; Mizuno Y; Mason RP;
    J Am Coll Cardiol; 2008 Mar; 51(12):1196-202. PubMed ID: 18355658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endothelial dysfunction and chronic kidney disease: treatment options.
    Wu-Wong JR
    Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia.
    Milicevic Z; Raz I; Beattie SD; Campaigne BN; Sarwat S; Gromniak E; Kowalska I; Galic E; Tan M; Hanefeld M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S155-60. PubMed ID: 18227478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Astaxanthin, oxidative stress, inflammation and cardiovascular disease.
    Fassett RG; Coombes JS
    Future Cardiol; 2009 Jul; 5(4):333-42. PubMed ID: 19656058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Training after percutaneous coronary intervention- an undervalued treatment option?].
    Munk PS; Larsen AI
    Tidsskr Nor Laegeforen; 2007 May; 127(10):1365-7. PubMed ID: 17519991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance measures have a major effect on cardiovascular outcomes: a review.
    Mehta RH; Peterson ED; Califf RM
    Am J Med; 2007 May; 120(5):398-402. PubMed ID: 17466646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.
    Chiang KH; Huang PH; Huang SS; Wu TC; Chen JW; Lin SJ
    Coron Artery Dis; 2009 Jun; 20(4):267-73. PubMed ID: 19440065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC
    Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular protection paradigms: is change on the horizon?
    Papademetriou V
    Rev Cardiovasc Med; 2007; 8(4):200-13. PubMed ID: 18192943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. More knocks to the oxidation hypothesis for vascular disease?
    Mullan A; Sattar N
    Clin Sci (Lond); 2009 Jan; 116(1):41-3. PubMed ID: 18844607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention.
    Watts GF; Chew KK; Stuckey BG
    Nat Clin Pract Cardiovasc Med; 2007 May; 4(5):263-73. PubMed ID: 17457350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.
    Nozaki T; Sugiyama S; Koga H; Sugamura K; Ohba K; Matsuzawa Y; Sumida H; Matsui K; Jinnouchi H; Ogawa H
    J Am Coll Cardiol; 2009 Aug; 54(7):601-8. PubMed ID: 19660689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of ET-1-induced endothelial dysfunction.
    Iglarz M; Clozel M
    J Cardiovasc Pharmacol; 2007 Dec; 50(6):621-8. PubMed ID: 18091577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelial dysfunction in obesity: etiological role in atherosclerosis.
    Meyers MR; Gokce N
    Curr Opin Endocrinol Diabetes Obes; 2007 Oct; 14(5):365-9. PubMed ID: 17940464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.